Mytos

Mytos automates the production of stem cell-derived regenerative medicines using proprietary robotics. Founded in 2016 by Ali Afshar and Ignacio Willats, who met during Afshar's PhD at Imperial College where he became frustrated by manual laboratory processes and began building robots to automate repetitive tasks. The platform takes stem cells (iPSCs) and fully automates their differentiation into specific cell types such as neurons and cardiac cells, replacing manual touchpoints with precisely controlled, programmable steps. In 2023, Mytos closed a $19M Series A led by Buckley Ventures, joined by IQ Capital and Wing VC. The company has launched its iDEM platform as an automated contract development and manufacturing organisation, with its first facility at the Cell and Gene Therapy Catapult's Stevenage Manufacturing Innovation Centre targeting clinical readiness by September 2026.